Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Hybrid PET/MRI in Neuro-oncology: Current Status and Perspectives

Version 1 : Received: 1 June 2023 / Approved: 1 June 2023 / Online: 1 June 2023 (12:54:09 CEST)

A peer-reviewed article of this Preprint also exists.

Langen, K.-J.; Galldiks, N.; Mauler, J.; Kocher, M.; Filß, C.P.; Stoffels, G.; Régio Brambilla, C.; Stegmayr, C.; Willuweit, A.; Worthoff, W.A.; Shah, N.J.; Lerche, C.; Mottaghy, F.M.; Lohmann, P. Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives. Cancers 2023, 15, 3577. Langen, K.-J.; Galldiks, N.; Mauler, J.; Kocher, M.; Filß, C.P.; Stoffels, G.; Régio Brambilla, C.; Stegmayr, C.; Willuweit, A.; Worthoff, W.A.; Shah, N.J.; Lerche, C.; Mottaghy, F.M.; Lohmann, P. Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives. Cancers 2023, 15, 3577.

Abstract

Advanced MRI methods and PET using radiolabeled amino acids provide valuable information in addition to conventional MR imaging for brain tumor diagnostics. These methods are particularly helpful in challenging situations such as the differentiation of malignant processes from benign lesions, the identification of non-enhancing glioma subregions, the differentiation of tumor progression from treatment-related changes, and the early assessment of response to anticancer therapy. The debate over which of the methods is preferable in which situation is ongoing and has been addressed in numerous studies. Currently, most radiology and nuclear medicine departments perform these examinations independently of each other leading to multiple examinations for the patient. The advent of hybrid PET/MRI allowed a convergence of the methods but to date simultaneous imaging has reached little relevance in clinical neuro-oncology. This is partly due to the limited availability of hybrid PET/MRI scanners, but is also due to the fact that PET is a second-line examination in brain tumors. PET is only required in equivocal situations, and spatial co-registration of PET examinations of the brain to previous MRI is possible without disadvantage. A key factor for the benefit of PET/MRI in neuro-oncology is a multimodal approach that provides decisive improvements in the diagnostics of brain tumors compared with a single modality. This systematic review focuses on studies that were able to demonstrate the additive value of amino acid PET and ‘advanced’ MRI in the diagnosis of brain tumors. Available studies suggest that the combination of amino acid PET and advanced MRI improves grading and the histomolecular characterization of newly diagnosed tumors. However, data concerning the delineation of tumor extent and biopsy guidance are of limited value. A clear additive diagnostic value of amino acid PET and advanced MRI can be achieved regarding the differentiation of tumor recurrence from treatment-related changes. Here, PET-guided evaluation of advanced MR methods seems to be helpful. In summary, there is growing evidence that a multimodal approach can achieve decisive improvements in the diagnostics of brain tumors, for which hybrid PET/MRI offers optimal conditions.

Keywords

brain tumor diagnosis; PET; radiolabeled amino acids; O-(2-[18F]fluoroethyl)-L-tyrosine (FET); Hybrid PET/MRI; multimodal imaging

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.